核酸分離・精製市場規模、シェア、動向、2030年までの世界予測

核酸分離・精製市場は、2025年の71億米ドルから2030年には109億9000万米ドルに成長し、予測期間中の年平均成長率（CAGR）は9.1%に達するとMarketsandMarketsでは予測しています。PCRやその他の核酸増幅検査（NAAT）ワークフローは、多くの感染症プログラムで日常的に使用されています。検査機関は検査項目を拡大し、より多くのサンプル量を処理しています。次世代シーケンシング（NGS）も臨床応用が進み、最初のステップとして高純度のDNA/RNAの必要性が高まっています。抽出品質の低下は、下流工程の感度に影響を与えます。そのため、エンドユーザーは信頼性の高いNAIPワークフローと試薬への投資を継続する必要があります。

調査範囲

本調査レポートは、核酸分離・精製市場を、製品別（キット、試薬、機器（手動、自動））、種類別（プラスミドDNA分離・精製、全RNA分離・精製、ゲノムDNA分離・精製、メッセンジャーRNA分離・精製、循環核酸分離・精製、マイクロRNA分離・精製、その他）、方法別（磁気ビーズ法、試薬法、カラム法、その他）、用途別（診断、創薬・開発、個別化医療、農業・動物研究、その他）、エンドユーザー別（病院・診断センター、学術・政府系研究機関、製薬・バイオテクノロジー企業、医薬品開発業務受託機関（CRO）、その他）、地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）に分類しています。本レポートでは、核酸分離・精製市場の成長に影響を与える主要な要因（推進要因、課題、機会、制約など）に関する詳細な情報を提供します。また、主要企業の詳細な分析を行い、事業概要、製品ポートフォリオ、製品発売、提携、パートナーシップ、事業拡大、契約などの主要戦略、および核酸分離・精製市場に関連する最近の動向について解説します。さらに、核酸分離・精製市場のエコシステムにおける主要企業および新興スタートアップ企業の競合分析も本レポートで取り上げています。

本レポートを購入する主なメリット

本レポートは、核酸分離・精製市場全体およびそのサブセグメントにおける収益の最も正確な予測値を提供することで、市場リーダー企業と新規参入企業を支援します。また、関係者が競争環境をより深く理解し、事業のポジショニングを改善し、適切な市場参入戦略を策定するための洞察を得るのに役立ちます。本レポートは、関係者が市場の動向を把握し、主要な市場推進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。

本レポートは、以下の点に関する洞察を提供します。

市場の成長に影響を与える主要な推進要因（医療および研究におけるルーチンPCR/qPCRおよびNGS検査の規模拡大、より多くの国における公衆衛生ゲノムサーベイランスの拡大）、阻害要因（大量検査に必要な高コストと時間）、機会（スループット、トレーサビリティ、人員配置の安定性に影響を与える自動化、cfDNA、腫瘍学、低インプットワークフロー向けの高機能NAIP製品）、および課題（PCR阻害物質およびマトリックス効果による変動）の分析。

• 製品開発／イノベーション：核酸分離・精製市場における新製品に関する詳細な分析
• 市場開発：有望な市場に関する包括的な情報 ― 本レポートは、様々な地域における市場を分析しています。
• 市場の多様化：核酸分離・精製市場における新製品、未開拓地域、最近の動向、投資に関する包括的な情報
• 競合分析：Thermo Fisher Scientific Inc.（米国）、Merck KGaA（ドイツ）、QIAGEN（ドイツ）、F. Hoffmann-La Roche Ltd.（スイス）、Promega Corporation（米国）、Agilent Technologies, Inc.（米国）、Danaher（米国）、Bio-Rad Laboratories, Inc.（米国）、Illumina, Inc.（米国）、タカラバイオ株式会社（日本）、New England Biolabs（米国）、Abcam Plc（英国）、KILPEST India Limited（インド）、Apical Scientific Sdn. Bhd.（マレーシア）、Endress+Hauser Group Services AG（スイス）、GENAXXON bioscience GmbH（ドイツ）、LGC Biosearch Technologies（米国）など

Report Description

The nucleic acid isolation and purification market is expected to grow from USD 7.10 billion in 2025 to USD 10.99 billion in 2030, at a CAGR of 9.1% during the forecast period. PCR and other NAAT workflows are routine in many infectious disease programs. Labs are expanding test menus and handling higher sample volumes. NGS is also moving deeper into clinical use cases, increasing the need for clean DNA/RNA as a first step. Declining extraction quality affects downstream sensitivity. This encourages end users to continue investing in reliable NAIP workflows and reagents.

“The magnetic-bead based isolation and purification segment accounted for the largest share, by method, in the nucleic acid isolation and purification market in 2024.”

The nucleic acid isolation and purification market is segmented into magnetic bead-based isolation and purification, column-based isolation and purification, reagent-based isolation and purification, and other methods. In 2024, the magnetic bead-based isolation and purification method dominated the market. This dominance is driven by the compatibility of bead workflows with automation and high-throughput processing, which are priorities for hospitals, reference labs, and large research centers. Bead-based methods also deliver consistent yields and reproducibility across batches, helping labs reduce reruns and maintain turnaround times.

“The diagnostics segment was the largest application segment in the nucleic acid isolation and purification market in 2024.”

The nucleic acid isolation and purification market is segmented by application into diagnostics, drug discovery & development, personalized medicine, agriculture & animal research, and other applications. The diagnostics segment led the market in 2024. The primary reason is that DNA/RNA extraction is a necessary first step for most PCR/NAAT assays. In addition, a growing number of sequencing-based clinical tests is supporting expansion. High routine volumes from infectious disease panels, respiratory testing, and oncology molecular assays maintain steady demand. Diagnostic labs also prioritize standardized and validated workflows to reduce variability, avoid reruns, and shorten turnaround times.

“The Asia Pacific region will grow at the highest CAGR in the nucleic acid isolation and purification market from 2025 to 2030.”

The Asia Pacific region is estimated to be the fastest-growing segment of the market. This growth is supported by the expansion of population genomics programs and the rising focus on precision medicine. The region is also seeing increased demand for diagnosis and monitoring of rare and genetic diseases, especially in aging populations in markets such as Japan and China. As a result, sequencing and other molecular testing are being adopted more widely in routine healthcare.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1- 40%, Tier 2- 30% and Tier 3- 30%
• By Designation: Directors- 20%, Managers- 10% and Others – 70%,
• By Region: North America -35%, Europe -25%, Asia Pacific -25%, Latin America -10%, and Middle East -5%.

List of Companies Profiled in the Report:

• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• QIAGEN (Germany)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Promega Corporation (US)
• Agilent Technologies, Inc. (US)
• Danaher(US)
• Bio-Rad Laboratories, Inc. (US)
• Illumina, Inc. (US)
• Takara Bio Inc. (Japan)
• New England Biolabs (US)
• Abcam Plc (UK)
• KILPEST India Limited (India)
• Apical Scientific Sdn. Bhd. (Malaysia)
• Endress+Hauser Group Services AG (Switzerland)
• GENAXXON bioscience GmbH (Germany)
• LGC Biosearch Technologies (US)
• Zymo Research Corporation (US)
• Norgen Biotek Corp. (Canada)
• Omega Bio-Tek, Inc. (US)
• FAVORGEN Biotech Corp. (China)
• TIANGEN Biotech (Beijing) Co., Ltd. (China)
• AutoGen Inc. (US)
• PCR Biosystems (UK)
• Biogenuix (India)

Research Coverage

This research report categorizes the nucleic acid isolation and purification market by product [Kits, Reagents, Instruments (Manual, Automatic)], by type (Plasmid DNA isolation and purification, Total RNA isolation and purification, Genomic DNA isolation and purification, Messenger RNA isolation and purification, Circulating nucleic acid isolation and purification, MicroRNA isolation and purification, Other types), by method (Magnetic bead-based isolation and purification, Reagent-based isolation and purification, Column-based isolation and purification, Other methods), by application (Diagnostics, Drug discovery & development, Personalized medicine, Agriculture and animal research, Other applications), by end user (Hospitals and diagnostic centers, Academic and government research institutes, Pharmaceutical and biotechnology companies, Contract Research Organizations (CROs), Other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information on the major factors, such as drivers, challenges, opportunities, and restraints, that influence the growth of the nucleic acid isolation and purification market. A detailed analysis of key industry players has been conducted to provide insights into their business overview, product portfolio, key strategies such as product launches, collaborations, partnerships, expansions, agreements, and recent developments associated with the nucleic acid isolation and purification market. Competitive analysis of top players and upcoming startups in the nucleic acid isolation and purification market ecosystem is also covered in this report.

Key Benefits of Buying the Report

The report will help market leaders and new entrants by providing the closest approximations of revenue for the overall nucleic acid isolation and purification market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain insights to better position their business and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following points:

Analysis of key drivers (routine PCR/qPCR and NGS testing scaling across care and research, expanding public health genomic surveillance in more countries), restraints (high cost and time required for high-volume testing), opportunities (automation impacting throughput, traceability, and staffing resilience, premium NAIP products for cfDNA, oncology, and low-input workflows), and challenges (variability due to PCR inhibitors and matrix effects) influencing the growth of the market.

• Product Development/Innovation: Detailed insights on newly launched products of the nucleic acid isolation and purification market
• Market Development: Comprehensive information about lucrative markets – the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the nucleic acid isolation and purification market
• Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), QIAGEN (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Promega Corporation (US), Agilent Technologies, Inc. (US), Danaher(US), Bio-Rad Laboratories, Inc. (US), Illumina, Inc. (US), Takara Bio Inc. (Japan), New England Biolabs (US), Abcam Plc (UK), KILPEST India Limited (India), Apical Scientific Sdn. Bhd. (Malaysia), Endress+Hauser Group Services AG (Switzerland), GENAXXON bioscience GmbH (Germany), and LGC Biosearch Technologies (US), among others

Table of Contents

1 INTRODUCTION 45
1.1 STUDY OBJECTIVES 45
1.2 MARKET DEFINITION 45
1.3 STUDY SCOPE 46
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 46
1.4 INCLUSIONS & EXCLUSIONS 47
1.4.1 YEARS CONSIDERED 48
1.4.2 CURRENCY CONSIDERED 48
1.5 STAKEHOLDERS 49
1.6 SUMMARY OF CHANGES 49
2 EXECUTIVE SUMMARY 51
2.1 MARKET HIGHLIGHTS & KEY INSIGHTS 51
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS 53
2.3 DISRUPTIVE TRENDS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 54
2.4 HIGH-GROWTH SEGMENTS 55
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST 56
3 PREMIUM INSIGHTS 58
3.1 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET OVERVIEW 58
3.2 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT 59
3.3 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 60
3.4 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SHARE, BY END USER,
2026 VS 2031 (%) 61
4 MARKET OVERVIEW 62
4.1 INTRODUCTION 62
4.2 MARKET DYNAMICS 62
4.2.1 DRIVERS 64
4.2.1.1 Rising adoption of automated nucleic acid extraction systems 64
4.2.1.2 Increasing need for high-purity and inhibitor-free nucleic acid recovery 64
4.2.1.3 Broadening use of magnetic bead-based purification chemistries 65
4.2.1.4 Growth in complex and difficult sample-type processing 65
4.2.2 RESTRAINTS 65
4.2.2.1 Price pressure and partial commoditization of routine extraction kits 65
4.2.2.2 Continued use of manual and low-cost in-house methods in small & mid-sized labs 66
4.2.2.3 Workflow substitution in selected use cases 66
4.2.3 OPPORTUNITIES 66
4.2.3.1 Premium extraction solutions for low-input and cell-free nucleic acids 66
4.2.3.2 Expansion of automated benchtop and mid-throughput extraction platforms 67
4.2.3.3 Workflow integration with quantitation, tracking, and digital reporting 67
4.2.3.4 Application-specific extraction workflows in biopharma and CGT 67
4.2.4 CHALLENGES 68
4.2.4.1 Pre-analytical variability that affects extraction output 68
4.2.4.2 Removal of inhibitors and contaminants from difficult matrices 68
4.2.4.3 Standardization and validation for regulated or sensitive workflows 68
4.3 UNMET NEEDS & WHITE SPACES 69
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 70
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 72
5 INDUSTRY TRENDS 73
5.1 PORTER’S FIVE FORCES ANALYSIS 73
5.1.1 THREAT OF NEW ENTRANTS 74
5.1.2 THREAT OF SUBSTITUTES 74
5.1.3 BARGAINING POWER OF BUYERS 74
5.1.4 BARGAINING POWER OF SUPPLIERS 74
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 74
5.2 MACROECONOMIC OUTLOOK 75
5.2.1 INTRODUCTION 75
5.2.2 GDP TRENDS & FORECAST 75
5.2.3 TRENDS IN GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 75
5.2.4 TRENDS IN HEALTHCARE EXPENDITURE 77
5.3 VALUE CHAIN ANALYSIS 78
5.4 SUPPLY CHAIN ANALYSIS 81
5.5 ECOSYSTEM ANALYSIS 82
5.5.1 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS 83
5.6 PRICING ANALYSIS 85
5.6.1 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2025 85
5.6.2 INDICATIVE SELLING PRICE OF NAIP PRODUCTS, BY REGION, 2025 86
5.7 KEY CONFERENCES & EVENTS 87
5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 88
5.9 INVESTMENT/FUNDING ACTIVITY 89
5.10 CASE STUDY ANALYSIS 90
5.11 IMPACT OF 2025 US TARIFFS ON NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 92
5.11.1 INTRODUCTION 92
5.11.2 KEY TARIFF RATES 92
5.11.3 PRICE IMPACT ANALYSIS 93
5.11.4 IMPACT ON COUNTRY/REGION 94
5.11.4.1 US 94
5.11.4.2 Europe 94
5.11.4.3 Asia Pacific 94
5.11.5 IMPACT ON END-USE INDUSTRIES 95
5.11.5.1 Hospitals & diagnostic centers 95
5.11.5.2 Academic & government research institutes 95
5.11.5.3 Pharmaceutical & biotechnology companies 96
5.11.5.4 Contract research organizations (CROs) 96
5.11.5.5 Other end users 96
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 98
6.1 TECHNOLOGY ANALYSIS 98
6.1.1 KEY TECHNOLOGIES 98
6.1.1.1 Silica membrane/spin column purification 98
6.1.1.2 Magnetic bead-based purification 98
6.1.1.3 Reagent-based extraction/organic extraction 98
6.1.2 COMPLEMENTARY TECHNOLOGIES 99
6.1.2.1 Sample lysis & homogenization technologies 99
6.1.2.2 Centrifugation & vacuum manifold systems 99
6.1.3 ADJACENT TECHNOLOGIES 99
6.1.3.1 PCR & qPCR technologies 99
6.2 TECHNOLOGY/PRODUCT ROADMAP 99
6.3 PATENT ANALYSIS 102
6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR NUCLEIC ACID ISOLATION AND PURIFICATION PRODUCT/TECHNOLOGY PATENTS, 2015–2025 102
6.4 FUTURE APPLICATIONS 104
6.5 IMPACT OF AI/GEN AI ON NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 104
6.5.1 TOP USE CASES & MARKET POTENTIAL 105
6.5.2 CASE STUDIES OF AI IMPLEMENTATION IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 106
6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS 107
6.5.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 107
6.6 SUCCESS STORIES & REAL-WORLD APPLICATIONS 108
7 SUSTAINABILITY & REGULATORY LANDSCAPE 110
7.1 REGULATORY LANDSCAPE 110
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110
7.1.2 REGULATORY FRAMEWORK/KEY REGULATIONS 112
7.1.2.1 North America 112
7.1.2.1.1 US 112
7.1.2.1.2 Canada 114
7.1.2.2 Europe 115
7.1.2.2.1 Germany 115
7.1.2.2.2 France 116
7.1.2.2.3 UK 116
7.1.2.3 Asia Pacific 116
7.1.2.3.1 Japan 116
7.1.2.3.2 China 117
7.1.2.3.3 India 118
7.1.2.3.4 South Korea 118
7.1.2.4 Latin America 119
7.1.2.4.1 Brazil 119
7.1.2.5 Middle East 120
7.1.2.5.1 Saudi Arabia 120
7.1.3 INDUSTRY STANDARDS 120
7.2 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 121
7.3 CERTIFICATIONS, LABELING, AND ECO-STANDARDS 122
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 123
8.1 DECISION-MAKING PROCESS 123
8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 123
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 123
8.2.2 KEY BUYING CRITERIA, BY END USER 124
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 125
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 126
8.5 MARKET PROFITABILITY 127
9 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT 128
9.1 INTRODUCTION 129
9.2 KITS 130
9.2.1 KITS TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING
FORECAST PERIOD 130
9.3 REAGENTS 134
9.3.1 AVAILABILITY OF READY-TO-USE REAGENTS TO DRIVE GROWTH 134
9.4 INSTRUMENTS 138
9.4.1 AUTOMATIC INSTRUMENTS 142
9.4.1.1 Benefits of automatic instruments to drive growth 142
9.4.2 MANUAL INSTRUMENTS 146
9.4.2.1 Growing demand for nucleic acid isolation and purification in research and clinical applications to drive growth 146

10 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD 150
10.1 INTRODUCTION 151
10.2 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION 151
10.2.1 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION SEGMENT TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 151
10.3 REAGENT-BASED ISOLATION AND PURIFICATION 155
10.3.1 REAGENT-BASED ISOLATION AND PURIFICATION SEGMENT TO REGISTER STEADY GROWTH DURING FORECAST PERIOD 155
10.4 COLUMN-BASED ISOLATION AND PURIFICATION 159
10.4.1 GROWING POPULARITY OF COLUMN-BASED ISOLATION AND PURIFICATION IN CURRENT KITS TO BOOST MARKET 159
10.5 OTHER ISOLATION AND PURIFICATION METHODS 163
11 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE 167
11.1 INTRODUCTION 168
11.2 PLASMID DNA ISOLATION AND PURIFICATION 169
11.2.1 PLASMID DNA ISOLATION AND PURIFICATION TO ACCOUNT FOR LARGEST SHARE OF MARKET 169
11.3 TOTAL RNA ISOLATION AND PURIFICATION 173
11.3.1 WIDE USE OF TOTAL RNA ISOLATION AND PURIFICATION FOR RESEARCH AND DIAGNOSTIC APPLICATIONS TO BOOST MARKET 173
11.4 GENOMIC DNA ISOLATION AND PURIFICATION 176
11.4.1 IMPORTANCE OF GENOMIC DNA ISOLATION IN GENETIC-BASED TESTS TO SUPPORT GROWTH 176
11.5 MESSENGER RNA ISOLATION AND PURIFICATION 180
11.5.1 ROLE PLAYED BY MESSENGER RNA ISOLATION AND PURIFICATION IN GENE EXPRESSION AND TRANSCRIPTOMICS TO DRIVE GROWTH 180
11.6 CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION 184
11.6.1 ABILITY OF CIRCULATING NAIP TO ENABLE COLLECTION OF GENETIC INFORMATION FROM BODY FLUIDS TO BOOST ADOPTION 184
11.7 MICRORNA ISOLATION AND PURIFICATION 187
11.7.1 GROWING APPLICATIONS OF MICRORNA ISOLATION AND PURIFICATION IN DRUG DEVELOPMENT RESEARCH TO FUEL GROWTH 187
11.8 OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES 191
12 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE 195
12.1 INTRODUCTION 196
12.2 CELLULAR SAMPLES 196
12.2.1 WBCS 201
12.2.1.1 Strong demand from routine blood-based genomics and diagnostic testing workflows to boost market 201
12.2.2 CULTURED CELLS 204
12.2.2.1 Core segment supporting drug discovery, cell biology, and biopharma R&D applications 204

12.2.3 BACTERIAL 208
12.2.3.1 Rising adoption in infectious disease, microbiome, and environmental testing workflows to fuel market growth 208
12.2.4 OTHER CELLULAR SAMPLES 211
12.3 PRESERVED TISSUE SAMPLES 215
12.3.1 FRESH/FROZEN TISSUES 219
12.3.1.1 Preferred for high-quality nucleic acid recovery in research and translational studies 219
12.3.2 FFPE (FORMALIN-FIXED PARAFFIN-EMBEDDED) 222
12.3.2.1 Fastest-growing segment fueled by increasing use of archived clinical samples in oncology 222
12.3.3 OTHER PRESERVED TISSUE SAMPLES 226
12.4 CELL-FREE SAMPLES 229
12.4.1 CFDNA/CTDNA 233
12.4.1.1 Key growth driver enabling liquid biopsy and real-time disease monitoring 233
12.4.2 OTHER CELL-FREE SAMPLES 237
12.5 OTHER SAMPLES 240
13 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION 244
13.1 INTRODUCTION 245
13.2 DIAGNOSTICS 245
13.2.1 DIAGNOSTIC APPLICATIONS TO DOMINATE MARKET DURING FORECAST PERIOD 245
13.3 DRUG DISCOVERY & DEVELOPMENT 249
13.3.1 POTENTIAL OF NAIP TO HELP IN DEVELOPMENT OF DRUGS FOR RARE DISEASES TO BOOST MARKET 249
13.4 PERSONALIZED MEDICINE 253
13.4.1 RISING INCIDENCE OF CANCER AND INCREASING RESEARCH AND FUNDING TO DRIVE GROWTH 253
13.5 AGRICULTURE & ANIMAL RESEARCH 257
13.5.1 FAVORABLE FUNDING SCENARIO TO SUPPORT MARKET GROWTH 257
13.6 OTHER APPLICATIONS 261
14 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER 265
14.1 INTRODUCTION 266
14.2 HOSPITALS & DIAGNOSTIC CENTERS 267
14.2.1 RISING FOCUS ON PERSONALIZED MEDICINE IN HOSPITALS TO DRIVE MARKET GROWTH 267
14.3 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 271
14.3.1 INCREASE IN RESEARCH INTENSITY TO DRIVE USAGE OF NUCLEIC ACID ISOLATION AND PURIFICATION SYSTEMS 271
14.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 275
14.4.1 INCREASING NUMBER OF RESEARCH PROJECTS IN GENOMICS AND RELATED AREAS TO DRIVE SEGMENT GROWTH 275
14.5 CONTRACT RESEARCH ORGANIZATIONS 279
14.5.1 CONTRACT RESEARCH ORGANIZATIONS TO REGISTER STEADY GROWTH DURING FORECAST PERIOD 279
14.6 OTHER END USERS 283
15 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION 287
15.1 INTRODUCTION 288
15.2 NORTH AMERICA 288
15.2.1 US 295
15.2.1.1 Government and private funding to support market growth 295
15.2.2 CANADA 301
15.2.2.1 Growing investments in genomics to boost market demand 301
15.3 EUROPE 306
15.3.1 GERMANY 313
15.3.1.1 Germany to dominate market in Europe 313
15.3.2 UK 318
15.3.2.1 Government support for research through investments, funds,
and grants to support market growth 318
15.3.3 FRANCE 322
15.3.3.1 Increasing number of established biotech facilities to drive
market growth 322
15.3.4 ITALY 326
15.3.4.1 Government support to drive market growth in Italy 326
15.3.5 SPAIN 331
15.3.5.1 High adoption of advanced diagnostic technologies to drive market growth in Spain 331
15.3.6 REST OF EUROPE 336
15.4 ASIA PACIFIC 340
15.4.1 CHINA 348
15.4.1.1 Strong domestic genomics scale and tightening IVD framework to drive NAIP adoption 348
15.4.2 JAPAN 353
15.4.2.1 Whole-genome medicine and structured clinical implementation to support premium NAIP demand 353
15.4.3 INDIA 357
15.4.3.1 National genomics initiatives and rising domestic manufacturing to expand NAIP opportunities 357
15.4.4 AUSTRALIA 362
15.4.4.1 Precision health funding and rare-disease genomics to support advanced NAIP workflows 362
15.4.5 SOUTH KOREA 366
15.4.5.1 Support from governments to drive market in region 366
15.4.6 REST OF ASIA PACIFIC (ROAPAC) 371

15.5 LATIN AMERICA 375
15.5.1 BRAZIL 380
15.5.1.1 Brazil to dominate LATAM market 380
15.5.2 MEXICO 384
15.5.2.1 Favorable trade agreements to support imports and improve access to NAIP instruments in Mexico 384
15.5.3 REST OF LATIN AMERICA 389
15.6 MIDDLE EAST 393
15.6.1 GCC COUNTRIES 398
15.6.1.1 Saudi Arabia 403
15.6.1.1.1 National genomics strategy and precision medicine expansion to accelerate NAIP demand 403
15.6.1.2 UAE 407
15.6.1.2.1 Molecular lab standardization and genomics-led healthcare investment to strengthen NAIP adoption 407
15.6.1.3 Rest of GCC Countries 411
15.6.2 REST OF MIDDLE EAST 416
15.7 AFRICA 421
15.7.1 GOVERNMENT SUPPORT FOR RESEARCH STUDIES TO FUEL GROWTH 421
16 COMPETITIVE LANDSCAPE 426
16.1 INTRODUCTION 426
16.2 STRATEGIES ADOPTED BY KEY PLAYERS/RIGHT TO WIN 426
16.3 REVENUE ANALYSIS, 2021–2025 428
16.4 MARKET SHARE ANALYSIS, 2025 429
16.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 431
16.5.1 STARS 431
16.5.2 EMERGING LEADERS 431
16.5.3 PERVASIVE PLAYERS 432
16.5.4 PARTICIPANTS 432
16.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 433
16.5.5.1 Company footprint 433
16.5.5.2 Region footprint 434
16.5.5.3 Product footprint 435
16.5.5.4 Method footprint 436
16.5.5.5 Application footprint 437
16.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 438
16.6.1 PROGRESSIVE COMPANIES 438
16.6.2 RESPONSIVE COMPANIES 438
16.6.3 DYNAMIC COMPANIES 438
16.6.4 STARTING BLOCKS 438

16.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025 440
16.6.5.1 List of key startups/SMEs 440
16.6.5.2 Competitive benchmarking of key startups/SMEs 441
16.7 COMPANY VALUATION & FINANCIAL METRICS 442
16.7.1 FINANCIAL METRICS 442
16.7.2 COMPANY VALUATION 442
16.8 BRAND/PRODUCT COMPARISON 443
16.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT 443
16.9 COMPETITIVE SCENARIO 444
16.9.1 PRODUCT LAUNCHES 444
16.9.2 DEALS 445
17 COMPANY PROFILES 447
17.1 KEY PLAYERS 447
17.1.1 THERMO FISHER SCIENTIFIC INC. 447
17.1.1.1 Business overview 447
17.1.1.2 Products offered 448
17.1.1.3 Recent developments 450
17.1.1.3.1 Product launches 450
17.1.1.3.2 Expansions 450
17.1.1.3.3 Other developments 451
17.1.1.4 MnM view 451
17.1.1.4.1 Key strengths 451
17.1.1.4.2 Strategic choices 451
17.1.1.4.3 Weaknesses & competitive threats 451
17.1.2 QIAGEN N.V. 452
17.1.2.1 Business overview 452
17.1.2.2 Products offered 453
17.1.2.3 Recent developments 454
17.1.2.3.1 Product launches 454
17.1.2.3.2 Deals 455
17.1.2.4 MnM view 455
17.1.2.4.1 Key strengths 455
17.1.2.4.2 Strategic choices 455
17.1.2.4.3 Weaknesses & competitive threats 455
17.1.3 MERCK KGAA 456
17.1.3.1 Business overview 456
17.1.3.2 Products offered 457
17.1.3.3 Recent developments 461
17.1.3.3.1 Product launches 461
17.1.3.4 MnM view 462
17.1.3.4.1 Key strengths 462
17.1.3.4.2 Strategic choices 462
17.1.3.4.3 Weaknesses & competitive threats 462
17.1.4 F. HOFFMANN-LA ROCHE LTD. 463
17.1.4.1 Business overview 463
17.1.4.2 Products offered 464
17.1.4.3 Recent developments 467
17.1.4.3.1 Other developments 467
17.1.4.4 MnM view 467
17.1.4.4.1 Key strengths 467
17.1.4.4.2 Strategic choices 467
17.1.4.4.3 Weaknesses & competitive threats 467
17.1.5 DANAHER CORPORATION 468
17.1.5.1 Business overview 468
17.1.5.2 Products offered 469
17.1.5.3 Recent developments 472
17.1.5.3.1 Deals 472
17.1.5.4 MnM view 472
17.1.5.4.1 Key strengths 472
17.1.5.4.2 Strategic choices 473
17.1.5.4.3 Weaknesses & competitive threats 473
17.1.6 PROMEGA CORPORATION 474
17.1.6.1 Business overview 474
17.1.6.2 Products offered 474
17.1.6.3 Recent developments 477
17.1.6.3.1 Deals 477
17.1.7 AGILENT TECHNOLOGIES, INC. 478
17.1.7.1 Business overview 478
17.1.7.2 Products offered 479
17.1.7.3 Recent developments 480
17.1.7.3.1 Other Developments 480
17.1.8 BIO-RAD LABORATORIES, INC. 481
17.1.8.1 Business overview 481
17.1.8.2 Products offered 483
17.1.9 ILLUMINA, INC. 484
17.1.9.1 Business overview 484
17.1.9.2 Products offered 485
17.1.9.3 Recent developments 486
17.1.9.3.1 Product launches 486
17.1.10 TAKARA BIO INC. 487
17.1.10.1 Business overview 487
17.1.10.2 Products offered 488

17.1.11 NEW ENGLAND BIOLABS 492
17.1.11.1 Business overview 492
17.1.11.2 Products offered 492
17.1.11.3 Recent developments 495
17.1.11.3.1 Product launches 495
17.1.12 A&A BIOTECHNOLOGY 496
17.1.12.1 Business overview 496
17.1.12.2 Products offered 497
17.1.13 REVVITY INC. 498
17.1.13.1 Business overview 498
17.1.13.2 Products offered 500
17.1.14 BIONEER CORPORATION 501
17.1.14.1 Business overview 501
17.1.14.2 Products offered 502
17.1.15 HIMEDIA LABORATORIES PRIVATE LIMITED 503
17.1.15.1 Business overview 503
17.1.15.2 Products offered 503
17.2 OTHER PLAYERS 504
17.2.1 KILPEST INDIA LIMITED 504
17.2.2 APICAL SCIENTIFIC SDN. BHD. 505
17.2.3 ENDRESS+HAUSER GROUP SERVICES AG 506
17.2.4 GENAXXON BIOSCIENCE GMBH 507
17.2.5 LGC BIOSEARCH TECHNOLOGIES 508
17.2.6 ZYMO RESEARCH CORPORATION 509
17.2.7 NORGEN BIOTEK CORP. 512
17.2.8 OMEGA BIO-TEK, INC. 513
17.2.9 FAVORGEN BIOTECH CORPORATION 515
17.2.10 TIANGEN BIOTECH(BEIJING)CO., LTD. 516
17.2.11 AUTOGEN INC. 517
17.2.12 PCR BIOSYSTEMS 518
17.2.13 BIOGENUIX 519
17.2.14 MP BIOMEDICALS 520
17.2.15 NANJING VAZYME BIOTECH CO., LTD. 521
18 RESEARCH METHODOLOGY 522
18.1 RESEARCH DATA 522
18.1.1 SECONDARY DATA 523
18.1.1.1 Key data from secondary sources 523
18.1.2 PRIMARY DATA 524
18.1.2.1 Key data from primary sources 524
18.1.2.2 Key primary participants 524
18.1.2.3 Breakdown of primary interviews 525
18.1.2.4 Key industry insights 526
18.2 MARKET SIZE ESTIMATION 526
18.2.1 SEGMENTAL MARKET SIZE ESTIMATION 529
18.3 MARKET GROWTH RATE PROJECTIONS 531
18.4 FACTOR ANALYSIS 532
18.5 DATA TRIANGULATION 533
18.6 RESEARCH ASSUMPTIONS 534
18.7 RESEARCH LIMITATIONS & RISK ASSESSMENT 535
18.8 SRISK ASSESSMENT 535
19 APPENDIX 536
19.1 DISCUSSION GUIDE 536
19.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 540
19.3 CUSTOMIZATION OPTIONS 542
19.4 RELATED REPORTS 543
19.5 AUTHOR DETAILS 544

LIST OF TABLES

TABLE 1 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: IMPACT ANALYSIS 63
TABLE 2 NEXT-GENERATION SEQUENCING MARKET, BY REGION,
2024–2031 (USD MILLION) 70
TABLE 3 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: PORTER’S
FIVE FORCES ANALYSIS 74
TABLE 4 HEALTH EXPENDITURE AND FINANCING, 2015–2024 (IN PERCENTAGE OF GDP) 77
TABLE 5 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: ROLE IN ECOSYSTEM 82
TABLE 6 INDICATIVE SELLING PRICE OF KEY PLAYERS, BY PRODUCT, 2025 85
TABLE 7 INDICATIVE SELLING PRICE OF NAIP PRODUCTS, BY REGION, 2025 86
TABLE 8 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: KEY
CONFERENCES & EVENTS, 2026–2027 87
TABLE 9 CASE STUDY 1: DNA EXTRACTION FROM ARCHEOLOGICAL AND RECENT
SKELETAL REMAINS 90
TABLE 10 CASE STUDY 2: CLINICAL LAB AUTOMATION FOR ROUTINE MOLECULAR
SAMPLE PREPARATION 91
TABLE 11 CASE STUDY 3: AUTOMATED EXTRACTION OF FFPE SAMPLES FOR
ONCOLOGY/NGS WORKFLOWS 91
TABLE 12 US-ADJUSTED RECIPROCAL TARIFF RATES 92
TABLE 13 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: KEY COMPANIES’ TECHNOLOGY/PRODUCT ROADMAP 100
TABLE 14 DETAILED ANALYSIS OF KEY PATENTS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 103
TABLE 15 CASE STUDIES OF AI IMPLEMENTATION IN NUCLEIC ACID ISOLATION AND PURIFICATION 106
TABLE 16 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN NUCLEIC ACID ISOLATION
AND PURIFICATION MARKET 108
TABLE 17 KEY SUCCESS STORIES WITH RESPECT TO REAL-WORLD APPLICATION
IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 109
TABLE 18 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 110
TABLE 19 US FDA: MEDICAL DEVICE CLASSIFICATION 112
TABLE 20 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 113
TABLE 21 EUROPE: CLASSIFICATION OF DEVICES 115
TABLE 22 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 117
TABLE 23 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 117
TABLE 24 SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 119
TABLE 25 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT (%) 124
TABLE 26 KEY BUYING CRITERIA, BY END USER 124
TABLE 27 UNMET NEED ACROSS DIFFERENT END USERS IN NUCLEIC ACID ISOLATION
AND PURIFICATION MARKET 126
TABLE 28 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 129
TABLE 29 NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET, BY REGION,
2024–2031 (USD MILLION) 131
TABLE 30 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 131
TABLE 31 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 32 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 132
TABLE 33 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 34 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET,
BY REGION, 2024–2031 (USD MILLION) 133
TABLE 35 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION KITS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 133
TABLE 36 NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 135
TABLE 37 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 135
TABLE 38 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 39 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 136
TABLE 40 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 41 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 137
TABLE 42 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION REAGENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 137
TABLE 43 NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 139
TABLE 44 NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 139
TABLE 45 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 46 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 140
TABLE 47 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 48 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 141
TABLE 49 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY REGION, 2024–2031 (USD MILLION) 142
TABLE 50 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 142
TABLE 51 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 143
TABLE 52 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 143
TABLE 53 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 54 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 144
TABLE 55 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET
FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 56 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET
FOR AUTOMATIC INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 145
TABLE 57 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AUTOMATIC INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 145
TABLE 58 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 146
TABLE 59 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 60 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 147
TABLE 61 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 62 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 148
TABLE 63 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 149
TABLE 64 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR MANUAL INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 149
TABLE 65 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD,
2024–2031 (USD MILLION) 151
TABLE 66 MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET,
BY REGION, 2024–2031 (USD MILLION) 152
TABLE 67 NORTH AMERICA: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION
MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 68 EUROPE: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 153
TABLE 69 ASIA PACIFIC: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 70 LATIN AMERICA: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 154
TABLE 71 MIDDLE EAST: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET,
BY REGION, 2024–2031 (USD MILLION) 155
TABLE 72 GCC COUNTRIES: MAGNETIC BEAD-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 155
TABLE 73 REAGENT-BASED ISOLATION AND PURIFICATION MARKET, BY REGION,
2024–2031 (USD MILLION) 156
TABLE 74 NORTH AMERICA: REAGENT-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 75 EUROPE: REAGENT-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 157
TABLE 76 ASIA PACIFIC: REAGENT-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 77 LATIN AMERICA: REAGENT-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 158
TABLE 78 MIDDLE EAST: REAGENT-BASED ISOLATION AND PURIFICATION MARKET,
BY REGION, 2024–2031 (USD MILLION) 159
TABLE 79 GCC COUNTRIES: REAGENT-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 159
TABLE 80 COLUMN-BASED ISOLATION AND PURIFICATION MARKET, BY REGION,
2024–2031 (USD MILLION) 160
TABLE 81 NORTH AMERICA: COLUMN-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 160
TABLE 82 EUROPE: COLUMN-BASED ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 83 ASIA PACIFIC: COLUMN-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 161
TABLE 84 LATIN AMERICA: COLUMN-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 85 MIDDLE EAST: COLUMN-BASED ISOLATION AND PURIFICATION MARKET,
BY REGION, 2024–2031 (USD MILLION) 162
TABLE 86 GCC COUNTRIES: COLUMN-BASED ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 162
TABLE 87 OTHER ISOLATION AND PURIFICATION METHODS MARKET, BY REGION,
2024–2031 (USD MILLION) 163
TABLE 88 NORTH AMERICA: OTHER ISOLATION AND PURIFICATION METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 89 EUROPE: OTHER ISOLATION AND PURIFICATION METHODS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 164
TABLE 90 ASIA PACIFIC: OTHER ISOLATION AND PURIFICATION METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 91 LATIN AMERICA: OTHER ISOLATION AND PURIFICATION METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 165
TABLE 92 MIDDLE EAST: OTHER ISOLATION AND PURIFICATION METHODS MARKET,
BY REGION, 2024–2031 (USD MILLION) 166
TABLE 93 GCC COUNTRIES: OTHER ISOLATION AND PURIFICATION METHODS MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 166
TABLE 94 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 168
TABLE 95 PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY REGION,
2024–2031 (USD MILLION) 170
TABLE 96 NORTH AMERICA: PLASMID DNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 170
TABLE 97 EUROPE: PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 98 ASIA PACIFIC: PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 171
TABLE 99 LATIN AMERICA: PLASMID DNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 100 MIDDLE EAST: PLASMID DNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 172
TABLE 101 GCC COUNTRIES: PLASMID DNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 172
TABLE 102 TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY REGION,
2024–2031 (USD MILLION) 173
TABLE 103 NORTH AMERICA: TOTAL RNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 174
TABLE 104 EUROPE: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 174
TABLE 105 ASIA PACIFIC: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 106 LATIN AMERICA: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 175
TABLE 107 MIDDLE EAST: TOTAL RNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 176
TABLE 108 GCC COUNTRIES: TOTAL RNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 176
TABLE 109 GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY REGION,
2024–2031 (USD MILLION) 177
TABLE 110 NORTH AMERICA: GENOMIC DNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 111 EUROPE: GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 178
TABLE 112 ASIA PACIFIC: GENOMIC DNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 113 LATIN AMERICA: GENOMIC DNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 179
TABLE 114 MIDDLE EAST: GENOMIC DNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 180
TABLE 115 GCC COUNTRIES: GENOMIC DNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 180
TABLE 116 MESSENGER RNA ISOLATION AND PURIFICATION MARKET, BY REGION,
2024–2031 (USD MILLION) 181
TABLE 117 NORTH AMERICA: MESSENGER RNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 181
TABLE 118 EUROPE: MESSENGER RNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 119 ASIA PACIFIC: MESSENGER RNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 182
TABLE 120 LATIN AMERICA: MESSENGER RNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 121 MIDDLE EAST: MESSENGER RNA ISOLATION AND PURIFICATION MARKET,
BY REGION, 2024–2031 (USD MILLION) 183
TABLE 122 GCC COUNTRIES: MESSENGER RNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 183
TABLE 123 CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 184
TABLE 124 NORTH AMERICA: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 125 EUROPE: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 185
TABLE 126 ASIA PACIFIC: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 127 LATIN AMERICA: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 186
TABLE 128 MIDDLE EAST: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 187
TABLE 129 GCC COUNTRIES: CIRCULATING NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 187
TABLE 130 MICRORNA ISOLATION AND PURIFICATION MARKET, BY REGION,
2024–2031 (USD MILLION) 188
TABLE 131 NORTH AMERICA: MICRORNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 188
TABLE 132 EUROPE: MICRORNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY,
2024–2031 (USD MILLION) 189
TABLE 133 ASIA PACIFIC: MICRORNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 189
TABLE 134 LATIN AMERICA: MICRORNA ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 135 MIDDLE EAST: MICRORNA ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 190
TABLE 136 GCC COUNTRIES: MICRORNA ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 190
TABLE 137 OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY REGION, 2024–2031 (USD MILLION) 191
TABLE 138 NORTH AMERICA: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 139 EUROPE: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 192
TABLE 140 ASIA PACIFIC: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 141 LATIN AMERICA: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 193
TABLE 142 MIDDLE EAST: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY REGION, 2024–2031 (USD MILLION) 194
TABLE 143 GCC COUNTRIES: OTHER NUCLEIC ACID ISOLATION AND PURIFICATION TYPES MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 194
TABLE 144 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE,
2024–2031 (USD MILLION) 196
TABLE 145 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 197
TABLE 146 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY REGION, 2024–2031 (USD MILLION) 198
TABLE 147 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 198
TABLE 148 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 149 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 199
TABLE 150 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 151 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY REGION, 2024–2031 (USD MILLION) 200
TABLE 152 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 200
TABLE 153 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY REGION, 2024–2031 (USD MILLION) 201
TABLE 154 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 155 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS,
BY COUNTRY, 2024–2031 (USD MILLION) 202
TABLE 156 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 157 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY COUNTRY, 2024–2031 (USD MILLION) 203
TABLE 158 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY REGION, 2024–2031 (USD MILLION) 204
TABLE 159 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR WBCS, BY COUNTRY, 2024–2031 (USD MILLION) 204
TABLE 160 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS,
BY REGION, 2024–2031 (USD MILLION) 205
TABLE 161 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 205
TABLE 162 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 163 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 206
TABLE 164 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 165 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY REGION, 2024–2031 (USD MILLION) 207
TABLE 166 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CULTURED CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 207
TABLE 167 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS,
BY REGION, 2024–2031 (USD MILLION) 208
TABLE 168 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 169 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 209
TABLE 170 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 171 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 210
TABLE 172 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY REGION, 2024–2031 (USD MILLION) 211
TABLE 173 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR BACTERIAL CELLS, BY COUNTRY, 2024–2031 (USD MILLION) 211
TABLE 174 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY REGION, 2024–2031 (USD MILLION) 212
TABLE 175 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 212
TABLE 176 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 177 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 213
TABLE 178 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 179 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY REGION, 2024–2031 (USD MILLION) 214
TABLE 180 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELLULAR SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 214
TABLE 181 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 215
TABLE 182 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 216
TABLE 183 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 216
TABLE 184 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 185 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 217
TABLE 186 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 187 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 218
TABLE 188 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 218
TABLE 189 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY REGION, 2024–2031 (USD MILLION) 219
TABLE 190 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 191 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 220
TABLE 192 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 193 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 221
TABLE 194 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY REGION, 2024–2031 (USD MILLION) 222
TABLE 195 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FRESH/FROZEN TISSUES, BY COUNTRY, 2024–2031 (USD MILLION) 222
TABLE 196 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY REGION, 2024–2031 (USD MILLION) 223
TABLE 197 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY COUNTRY, 2024–2031 (USD MILLION) 223
TABLE 198 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 199 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE,
BY COUNTRY, 2024–2031 (USD MILLION) 224
TABLE 200 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 201 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY REGION, 2024–2031 (USD MILLION) 225
TABLE 202 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR FFPE, BY COUNTRY, 2024–2031 (USD MILLION) 225
TABLE 203 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 226
TABLE 204 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 205 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 227
TABLE 206 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 207 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 228
TABLE 208 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 229
TABLE 209 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER PRESERVED TISSUE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 229
TABLE 210 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 230
TABLE 211 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 230
TABLE 212 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 213 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 231
TABLE 214 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 215 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 232
TABLE 216 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
CELL-FREE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 233
TABLE 217 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 233
TABLE 218 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA,
BY REGION, 2024–2031 (USD MILLION) 234
TABLE 219 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 234
TABLE 220 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 221 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 235
TABLE 222 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 223 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY REGION, 2024–2031 (USD MILLION) 236
TABLE 224 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CFDNA/CTDNA, BY COUNTRY, 2024–2031 (USD MILLION) 236
TABLE 225 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 237
TABLE 226 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 227 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER
CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 238
TABLE 228 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 229 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 239
TABLE 230 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY REGION, 2024–2031 (USD MILLION) 240
TABLE 231 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER CELL-FREE SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 240
TABLE 232 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES,
BY REGION, 2024–2031 (USD MILLION) 241
TABLE 233 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 241
TABLE 234 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 235 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 242
TABLE 236 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 237 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY REGION, 2024–2031 (USD MILLION) 243

TABLE 238 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER SAMPLES, BY COUNTRY, 2024–2031 (USD MILLION) 243
TABLE 239 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION,
2024–2031 (USD MILLION) 245
TABLE 240 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 246
TABLE 241 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 246
TABLE 242 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 243 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 247
TABLE 244 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 245 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 248
TABLE 246 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 248
TABLE 247 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY
& DEVELOPMENT APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 250
TABLE 248 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 250
TABLE 249 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 251
TABLE 250 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 251
TABLE 251 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 252
TABLE 252 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 252
TABLE 253 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR DRUG DISCOVERY & DEVELOPMENT APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 252
TABLE 254 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 254
TABLE 255 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 254
TABLE 256 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 255
TABLE 257 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 255
TABLE 258 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 256
TABLE 259 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 256
TABLE 260 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PERSONALIZED MEDICINE APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 256
TABLE 261 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 258
TABLE 262 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 258
TABLE 263 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 264 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 259
TABLE 265 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 260
TABLE 266 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY REGION,
2024–2031 (USD MILLION) 260
TABLE 267 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR AGRICULTURE & ANIMAL RESEARCH APPLICATIONS, BY COUNTRY,
2024–2031 (USD MILLION) 260
TABLE 268 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER
APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 261
TABLE 269 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 270 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 262
TABLE 271 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 272 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 263
TABLE 273 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
OTHER APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 264
TABLE 274 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 264
TABLE 275 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER,
2024–2031 (USD MILLION) 266
TABLE 276 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2024–2031 (USD MILLION) 268
TABLE 277 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 268
TABLE 278 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 279 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 269
TABLE 280 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 270

TABLE 281 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2024–2031 (USD MILLION) 270
TABLE 282 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 270
TABLE 283 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 272
TABLE 284 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY,
2024–2031 (USD MILLION) 272
TABLE 285 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 273
TABLE 286 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY,
2024–2031 (USD MILLION) 273
TABLE 287 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY,
2024–2031 (USD MILLION) 274
TABLE 288 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION,
2024–2031 (USD MILLION) 274
TABLE 289 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY COUNTRY,
2024–2031 (USD MILLION) 274
TABLE 290 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL
& BIOTECHNOLOGY COMPANIES, BY REGION, 2024–2031 (USD MILLION) 276
TABLE 291 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 276
TABLE 292 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2024–2031 (USD MILLION) 277
TABLE 293 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 277
TABLE 294 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 278
TABLE 295 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,
2024–2031 (USD MILLION) 278
TABLE 296 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2024–2031 (USD MILLION) 279
TABLE 297 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 280
TABLE 298 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 280
TABLE 299 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 300 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 281
TABLE 301 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 302 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024–2031 (USD MILLION) 282
TABLE 303 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 282
TABLE 304 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS,
BY REGION, 2024–2031 (USD MILLION) 283
TABLE 305 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 306 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER
END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 284
TABLE 307 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 308 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 285
TABLE 309 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
OTHER END USERS, BY REGION, 2024–2031 (USD MILLION) 286
TABLE 310 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION) 286
TABLE 311 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION,
2024–2031 (USD MILLION) 288
TABLE 312 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 289
TABLE 313 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 290
TABLE 314 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290
TABLE 315 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY METHOD, 2024–2031 (USD MILLION) 291
TABLE 316 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY TYPE, 2024–2031 (USD MILLION) 292
TABLE 317 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY SAMPLE TYPE, 2024–2031 (USD MILLION) 292
TABLE 318 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 319 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 293
TABLE 320 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 294
TABLE 321 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 294
TABLE 322 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 295
TABLE 323 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 296
TABLE 324 US: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 296
TABLE 325 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD,
2024–2031 (USD MILLION) 297
TABLE 326 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 298
TABLE 327 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 298
TABLE 328 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 299
TABLE 329 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 299
TABLE 330 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 300
TABLE 331 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 300
TABLE 332 US: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER,
2024–2031 (USD MILLION) 301
TABLE 333 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 302
TABLE 334 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 302
TABLE 335 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 302
TABLE 336 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 303
TABLE 337 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 303
TABLE 338 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 339 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 340 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 304
TABLE 341 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 305
TABLE 342 CANADA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 305
TABLE 343 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 306
TABLE 344 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 307
TABLE 345 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 307
TABLE 346 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 308
TABLE 347 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 309
TABLE 348 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 310
TABLE 349 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 310
TABLE 350 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 311
TABLE 351 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 311
TABLE 352 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 312
TABLE 353 EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 312
TABLE 354 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 313
TABLE 355 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 313
TABLE 356 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 314
TABLE 357 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 314
TABLE 358 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 315
TABLE 359 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 315
TABLE 360 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 361 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 316
TABLE 362 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 317
TABLE 363 GERMANY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 317
TABLE 364 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 318
TABLE 365 UK: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 318
TABLE 366 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD,
2024–2031 (USD MILLION) 319
TABLE 367 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 319
TABLE 368 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 320
TABLE 369 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 370 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 320
TABLE 371 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 321
TABLE 372 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 321
TABLE 373 UK: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER,
2024–2031 (USD MILLION) 322
TABLE 374 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 323
TABLE 375 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 323
TABLE 376 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 323
TABLE 377 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 324
TABLE 378 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 324
TABLE 379 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 380 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 381 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 325
TABLE 382 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 326
TABLE 383 FRANCE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 326
TABLE 384 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 327
TABLE 385 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 327
TABLE 386 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD,
2024–2031 (USD MILLION) 328
TABLE 387 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 328
TABLE 388 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 329
TABLE 389 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 390 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 329
TABLE 391 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 330
TABLE 392 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 330
TABLE 393 ITALY: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 331
TABLE 394 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 332
TABLE 395 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 332
TABLE 396 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD,
2024–2031 (USD MILLION) 332
TABLE 397 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 333
TABLE 398 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 333
TABLE 399 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 400 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 401 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 334
TABLE 402 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 335
TABLE 403 SPAIN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 335
TABLE 404 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 336
TABLE 405 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336
TABLE 406 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY METHOD, 2024–2031 (USD MILLION) 337
TABLE 407 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 337
TABLE 408 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY SAMPLE TYPE, 2024–2031 (USD MILLION) 338
TABLE 409 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 338
TABLE 410 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 411 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 339
TABLE 412 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 339
TABLE 413 REST OF EUROPE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 340
TABLE 414 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 342
TABLE 415 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 342
TABLE 416 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 343
TABLE 417 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 343
TABLE 418 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 344
TABLE 419 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 345
TABLE 420 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 345
TABLE 421 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 346
TABLE 422 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 346
TABLE 423 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 347
TABLE 424 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 347
TABLE 425 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 348
TABLE 426 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 349
TABLE 427 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 349
TABLE 428 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 350
TABLE 429 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 350
TABLE 430 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 431 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 432 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 351
TABLE 433 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 352
TABLE 434 CHINA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 352
TABLE 435 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 353
TABLE 436 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 353
TABLE 437 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 354
TABLE 438 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 354
TABLE 439 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 355
TABLE 440 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 441 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 355
TABLE 442 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 356
TABLE 443 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 356
TABLE 444 JAPAN: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 357
TABLE 445 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 358
TABLE 446 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 358
TABLE 447 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD,
2024–2031 (USD MILLION) 358
TABLE 448 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 359
TABLE 449 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 359
TABLE 450 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 360
TABLE 451 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 360
TABLE 452 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 360
TABLE 453 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 361
TABLE 454 INDIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 361
TABLE 455 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 362
TABLE 456 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362
TABLE 457 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 363
TABLE 458 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 363
TABLE 459 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 364
TABLE 460 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 364
TABLE 461 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 364
TABLE 462 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 365
TABLE 463 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 365
TABLE 464 AUSTRALIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 365
TABLE 465 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 366
TABLE 466 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 367
TABLE 467 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY METHOD, 2024–2031 (USD MILLION) 367
TABLE 468 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 368
TABLE 469 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 368
TABLE 470 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 369
TABLE 471 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 369
TABLE 472 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 369
TABLE 473 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 370
TABLE 474 SOUTH KOREA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 370
TABLE 475 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 371
TABLE 476 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 371
TABLE 477 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY METHOD, 2024–2031 (USD MILLION) 372
TABLE 478 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY TYPE, 2024–2031 (USD MILLION) 372
TABLE 479 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY SAMPLE TYPE, 2024–2031 (USD MILLION) 373
TABLE 480 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 481 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 373
TABLE 482 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 374
TABLE 483 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 374
TABLE 484 REST OF ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 374
TABLE 485 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 375
TABLE 486 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 376
TABLE 487 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 376
TABLE 488 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY METHOD, 2024–2031 (USD MILLION) 376
TABLE 489 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 377
TABLE 490 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY SAMPLE TYPE, 2024–2031 (USD MILLION) 377
TABLE 491 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 378
TABLE 492 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 378
TABLE 493 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR
CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 378
TABLE 494 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 379
TABLE 495 LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 379
TABLE 496 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 380
TABLE 497 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 380
TABLE 498 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 381
TABLE 499 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 381
TABLE 500 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 382
TABLE 501 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 382
TABLE 502 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 382
TABLE 503 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 383
TABLE 504 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 383
TABLE 505 BRAZIL: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 384
TABLE 506 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 385
TABLE 507 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 385
TABLE 508 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 385
TABLE 509 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 386
TABLE 510 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 386
TABLE 511 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 512 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 513 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 387
TABLE 514 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 388
TABLE 515 MEXICO: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 388
TABLE 516 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 389
TABLE 517 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 389
TABLE 518 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 390
TABLE 519 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 390
TABLE 520 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 391
TABLE 521 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 391
TABLE 522 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 391
TABLE 523 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 392
TABLE 524 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 392
TABLE 525 REST OF LATIN AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 393
TABLE 526 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY REGION, 2024–2031 (USD MILLION) 393
TABLE 527 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 394
TABLE 528 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 394
TABLE 529 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 394
TABLE 530 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 395
TABLE 531 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 395
TABLE 532 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 533 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 534 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 396
TABLE 535 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 397
TABLE 536 MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 397
TABLE 537 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY COUNTRY, 2024–2031 (USD MILLION) 398
TABLE 538 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 398
TABLE 539 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 399
TABLE 540 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY METHOD, 2024–2031 (USD MILLION) 399
TABLE 541 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 400
TABLE 542 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY SAMPLE TYPE, 2024–2031 (USD MILLION) 400
TABLE 543 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 401
TABLE 544 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 401
TABLE 545 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 401
TABLE 546 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 402
TABLE 547 GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 402
TABLE 548 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 403
TABLE 549 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 403
TABLE 550 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY METHOD, 2024–2031 (USD MILLION) 404
TABLE 551 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 404
TABLE 552 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 405
TABLE 553 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 405
TABLE 554 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 405
TABLE 555 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 406
TABLE 556 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 406
TABLE 557 SAUDI ARABIA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 407
TABLE 558 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT,
2024–2031 (USD MILLION) 408
TABLE 559 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 408
TABLE 560 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD,
2024–2031 (USD MILLION) 408
TABLE 561 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 409
TABLE 562 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 409
TABLE 563 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 564 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 565 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 410
TABLE 566 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 411
TABLE 567 UAE: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER,
2024–2031 (USD MILLION) 411
TABLE 568 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 412
TABLE 569 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 412
TABLE 570 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 412
TABLE 571 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE, 2024–2031 (USD MILLION) 413
TABLE 572 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 413
TABLE 573 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 574 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 575 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 414
TABLE 576 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 415
TABLE 577 REST OF GCC COUNTRIES: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 415
TABLE 578 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY PRODUCT, 2024–2031 (USD MILLION) 416
TABLE 579 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET, BY TYPE, 2024–2031 (USD MILLION) 416
TABLE 580 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY METHOD, 2024–2031 (USD MILLION) 417
TABLE 581 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY TYPE, 2024–2031 (USD MILLION) 417
TABLE 582 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY SAMPLE TYPE, 2024–2031 (USD MILLION) 418
TABLE 583 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 418
TABLE 584 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 585 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 419
TABLE 586 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY APPLICATION, 2024–2031 (USD MILLION) 420

TABLE 587 REST OF MIDDLE EAST: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET,
BY END USER, 2024–2031 (USD MILLION) 420
TABLE 588 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY PRODUCT, 2024–2031 (USD MILLION) 421
TABLE 589 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION INSTRUMENTS MARKET,
BY TYPE, 2024–2031 (USD MILLION) 422
TABLE 590 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY METHOD, 2024–2031 (USD MILLION) 422
TABLE 591 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY TYPE,
2024–2031 (USD MILLION) 423
TABLE 592 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY SAMPLE TYPE, 2024–2031 (USD MILLION) 423
TABLE 593 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELLULAR SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 424
TABLE 594 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR PRESERVED TISSUE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 424
TABLE 595 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET FOR CELL-FREE SAMPLES, BY TYPE, 2024–2031 (USD MILLION) 424
TABLE 596 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 425
TABLE 597 AFRICA: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, BY END USER, 2024–2031 (USD MILLION) 425
TABLE 598 STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, 2023−2026 426
TABLE 599 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: DEGREE OF COMPETITION 430
TABLE 600 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: REGION FOOTPRINT 434
TABLE 601 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: PRODUCT FOOTPRINT 435
TABLE 602 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: METHOD FOOTPRINT 436
TABLE 603 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: APPLICATION FOOTPRINT 437
TABLE 604 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: KEY STARTUPS/SMES 440
TABLE 605 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 441
TABLE 606 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET:
PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 444
TABLE 607 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: DEALS,
JANUARY 2023– APRIL 2026 445
TABLE 608 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 447
TABLE 609 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 448
TABLE 610 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES,
JANUARY 2023–APRIL 2026 450
TABLE 611 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2023–APRIL 2026 450
TABLE 612 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS,
JANUARY 2023–APRIL 2026 451
TABLE 613 QIAGEN N.V.: COMPANY OVERVIEW 452
TABLE 614 QIAGEN N.V.: PRODUCTS OFFERED 453
TABLE 615 QIAGEN N.V.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 454
TABLE 616 QIAGEN N.V.: DEALS, JANUARY 2023–APRIL 2026 455
TABLE 617 MERCK KGAA: COMPANY OVERVIEW 456

TABLE 618 MERCK KGAA: PRODUCTS OFFERED 457
TABLE 619 MERCK KGAA: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 461
TABLE 620 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 463
TABLE 621 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 464
TABLE 622 F. HOFFMANN-LA ROCHE LTD.: OTHER DEVELOPMENTS,
JANUARY 2023–APRIL 2026 467
TABLE 623 DANAHER CORPORATION: COMPANY OVERVIEW 468
TABLE 624 DANAHER CORPORATION: PRODUCTS OFFERED 469
TABLE 625 DANAHER CORPORATION: DEALS, JANUARY 2023–APRIL 2026 472
TABLE 626 PROMEGA CORPORATION: COMPANY OVERVIEW 474
TABLE 627 PROMEGA CORPORATION: PRODUCTS OFFERED 474
TABLE 628 PROMEGA CORPORATION: DEALS, JANUARY 2023–APRIL 2026 477
TABLE 629 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 478
TABLE 630 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED 479
TABLE 631 AGILENT TECHNOLOGIES, INC.: OTHER DEVELOPMENTS,
JANUARY 2023–APRIL 2026 480
TABLE 632 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 481
TABLE 633 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 483
TABLE 634 ILLUMINA, INC.: COMPANY OVERVIEW 484
TABLE 635 ILLUMINA, INC.: PRODUCTS OFFERED 485
TABLE 636 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 486
TABLE 637 TAKARA BIO INC.: COMPANY OVERVIEW 487
TABLE 638 TAKARA BIO INC.: PRODUCTS OFFERED 488
TABLE 639 NEW ENGLAND BIOLABS: COMPANY OVERVIEW 492
TABLE 640 NEW ENGLAND BIOLABS: PRODUCTS OFFERED 492
TABLE 641 NEW ENGLAND BIOLABS: PRODUCT LAUNCHES, JANUARY 2023–MARCH 2026 495
TABLE 642 A&A BIOTECHNOLOGY: COMPANY OVERVIEW 496
TABLE 643 A&A BIOTECHNOLOGY: PRODUCTS OFFERED 497
TABLE 644 REVVITY INC.: COMPANY OVERVIEW 498
TABLE 645 REVVITY INC.: PRODUCTS OFFERED 500
TABLE 646 BIONEER CORPORATION: COMPANY OVERVIEW 501
TABLE 647 BIONEER CORPORATION: PRODUCTS OFFERED 502
TABLE 648 HIMEDIA LABORATORIES PRIVATE LIMITED: COMPANY OVERVIEW 503
TABLE 649 HIMEDIA LABORATORIES PRIVATE LIMITED: PRODUCTS OFFERED 503
TABLE 650 KILPEST INDIA LIMITED: COMPANY OVERVIEW 504
TABLE 651 APICAL SCIENTIFIC SDN. BHD.: COMPANY OVERVIEW 505
TABLE 652 ENDRESS+HAUSER GROUP SERVICES AG: COMPANY OVERVIEW 506
TABLE 653 GENAXXON BIOSCIENCE GMBH: COMPANY OVERVIEW 507
TABLE 654 LGC BIOSEARCH TECHNOLOGIES: COMPANY OVERVIEW 508
TABLE 655 ZYMO RESEARCH CORPORATION: COMPANY OVERVIEW 509
TABLE 656 NORGEN BIOTEK CORP.: COMPANY OVERVIEW 512
TABLE 657 OMEGA BIO-TEK, INC.: COMPANY OVERVIEW 513
TABLE 658 FAVORGEN BIOTECH CORPORATION: COMPANY OVERVIEW 515
TABLE 659 TIANGEN BIOTECH(BEIJING)CO., LTD.: COMPANY OVERVIEW 516
TABLE 660 AUTOGEN INC.: COMPANY OVERVIEW 517
TABLE 661 PCR BIOSYSTEMS: COMPANY OVERVIEW 518
TABLE 662 BIOGENUIX: COMPANY OVERVIEW 519
TABLE 663 MP BIOMEDICALS: COMPANY OVERVIEW 520
TABLE 664 NANJING VAZYME BIOTECH CO., LTD.: COMPANY OVERVIEW 521
TABLE 665 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS 532
TABLE 666 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: RISK ANALYSIS 535

LIST OF FIGURES

FIGURE 1 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SEGMENTATION
& REGIONAL SCOPE 46
FIGURE 2 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: YEARS CONSIDERED 48
FIGURE 3 MARKET SCENARIO 51
FIGURE 4 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, 2024–2031 52
FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEIC ACID ISOLATION
AND PURIFICATION MARKET, 2023–2026 53
FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF NUCLEIC ACID ISOLATION
AND PURIFICATION MARKET 54
FIGURE 7 HIGH-GROWTH SEGMENTS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, 2026–2031 55
FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD 56
FIGURE 9 ADVANCEMENTS IN NUCLEIC ACID ISOLATION AND PURIFICATION
PLATFORMS TO DRIVE MARKET GROWTH 58
FIGURE 10 KITS ACCOUNTED FOR LARGEST SHARE OF NUCLEIC ACID ISOLATION AND PURIFICATION MARKET IN NORTH AMERICA IN 2025 59
FIGURE 11 ASIA PACIFIC IS LIKELY TO BE FASTEST-GROWING MARKET IN GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET DURING FORECAST PERIOD 60
FIGURE 12 HOSPITALS & DIAGNOSTIC CENTERS TO DOMINATE MARKET DURING
FORECAST PERIOD 61
FIGURE 13 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: DRIVERS,
RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 62
FIGURE 14 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: PORTER’S
FIVE FORCES ANALYSIS 73
FIGURE 15 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: VALUE CHAIN ANALYSIS 79
FIGURE 16 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: SUPPLY CHAIN ANALYSIS 81
FIGURE 17 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: ECOSYSTEM ANALYSIS 82
FIGURE 18 INDICATIVE SELLING PRICE OF NAIP PRODUCTS, BY TYPE, 2025 86
FIGURE 19 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
FIGURE 20 VC/PRIVATE EQUITY INVESTMENT TRENDS & STARTUP LANDSCAPE 89
FIGURE 21 TOP APPLICANTS/OWNERS (COMPANIES) FOR NUCLEIC ACID ISOLATION AND PURIFICATION PRODUCTS/TECHNOLOGY PATENTS, 2015–2025 102
FIGURE 22 IMPACT OF AI/GEN AI ON NUCLEIC ACID ISOLATION AND PURIFICATION MARKET 105
FIGURE 23 CANADA: REGULATORY PROCESS FOR MEDICAL DEVICES 114
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT 123
FIGURE 25 KEY BUYING CRITERIA, BY END USER 124
FIGURE 26 NORTH AMERICA: NUCLEIC ACID ISOLATION AND PURIFICATION
MARKET SNAPSHOT 289
FIGURE 27 ASIA PACIFIC: NUCLEIC ACID ISOLATION AND PURIFICATION MARKET SNAPSHOT 341
FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET, 2021–2025 (USD MILLION) 428
FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NUCLEIC ACID ISOLATION AND PURIFICATION MARKET (2025) 430
FIGURE 30 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY
EVALUATION MATRIX (KEY PLAYERS), 2025 432
FIGURE 31 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY FOOTPRINT 433
FIGURE 32 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY
EVALUATION MATRIX (STARTUPS/SMES), 2025 439
FIGURE 33 EV/EBITDA OF KEY VENDORS 442
FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 442
FIGURE 35 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY PRODUCT 443
FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 448
FIGURE 37 QIAGEN N.V.: COMPANY SNAPSHOT (2025) 453
FIGURE 38 MERCK KGAA: COMPANY SNAPSHOT (2025) 457
FIGURE 39 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 464
FIGURE 40 DANAHER CORPORATION: COMPANY SNAPSHOT (2025) 469
FIGURE 41 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2025) 479
FIGURE 42 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 482
FIGURE 43 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 485
FIGURE 44 TAKARA BIO INC.: COMPANY SNAPSHOT (2025) 488
FIGURE 45 REVVITY INC.: COMPANY SNAPSHOT (2025) 499
FIGURE 46 BIONEER CORPORATION: COMPANY SNAPSHOT (2025) 502
FIGURE 47 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: RESEARCH DESIGN 522
FIGURE 48 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: BREAKDOWN
OF PRIMARIES 525
FIGURE 49 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: INSIGHTS
FROM PRIMARIES 526
FIGURE 50 GLOBAL NUCLEIC ACID ISOLATION AND PURIFICATION MARKET
ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025 527
FIGURE 51 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2025) 527
FIGURE 52 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE
ANALYSIS (2025) 528
FIGURE 53 SEGMENTAL MARKET SIZE ESTIMATION: TOP-DOWN APPROACH 529
FIGURE 54 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: CAGR PROJECTIONS 531
FIGURE 55 NUCLEIC ACID ISOLATION AND PURIFICATION MARKET: DATA TRIANGULATION 533

---

---